GILD
Gilead Sciences, Inc.
- Healthcare
- US companies in Drug Manufacturers - General (9)
- NASDAQ · USD
- Mkt cap $196.8bn
$158.69
as of 26 Oct 2026, 1% below its 52-week high
Screens as less well placed to keep growing its dividend, though its cut-risk signals are low. Its valuation looks rich against its own history.
These scores are a resilience check on the dividend, not a recommendation to buy or sell. They are not financial advice.
- Trailing yield
- 2.05%Last 12 months of regular payments at today's price
- Forward yield
- 2.10%Each payment expected in the next 12 months, not the latest one doubled
- Earnings cover
- Not availableEarnings over dividends paid
- Cash cover
- 3.2×Free cash flow over dividends paid
- 5y dividend growth
- +3.0% a yearNo cut since FY2017
- Next ex-dividend date
- Estimated15 Dec 2026Quarterly dividend of about $0.81
Compared with US companies in Drug Manufacturers - General (9)
- Trailing yield is lower than 5 of the 8 other US companies in Drug Manufacturers - General.
- 5y dividend growth (as paid) is lower than 6 of the 7 other US companies in Drug Manufacturers - General with a 5y growth figure.
Quality
48
LowCapacity to keep growing the dividend
Risk
40
LowSignals of dividend-cut pressure
Trim
76
HighHow extended the valuation looks
Why Quality is 48
GILD against US companies in Drug Manufacturers - General (9)
Valuation against its own history
As of the last reported period (30 Jun 2026). P80 means the figure is higher than 80% of GILD’s past readings.
- Yield2.55%P13, poor for this measure
- FCF payout30.8%P11, good for this measure
- Net debt / EBITDA17.29P100, poor for this measure
- DGR 5y+3.0%P0, poor for this measure
- ROIC-9.6%P0, poor for this measure
Forecast your income with the GILD dividend calculator
Inspect surfaces history; it does not predict the future. Nothing here is financial advice or an instruction to buy or sell. Always do your own research. See the Terms of Service.